Vertex Additional Paid In Capital from 2010 to 2025

VRTX Stock  USD 510.18  0.00  0.00%   
Vertex Pharmaceuticals Additional Paid In Capital yearly trend continues to be fairly stable with very little volatility. Additional Paid In Capital is likely to outpace its year average in 2025. Additional Paid In Capital is the excess amount paid by investors over the par value of a company's shares, representing the additional capital contributed by shareholders. View All Fundamentals
 
Additional Paid In Capital  
First Reported
2010-03-31
Previous Quarter
7.4 B
Current Value
7.4 B
Quarterly Volatility
3.2 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 11.6 B, Gross Profit of 10 B or Other Operating Expenses of 11.8 B, as well as many indicators such as Price To Sales Ratio of 8.94, Dividend Yield of 0.0 or PTB Ratio of 7.39. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Additional Paid In Capital Growth Pattern

Below is the plot of the Additional Paid In Capital of Vertex Pharmaceuticals over the last few years. Additional Paid In Capital (or APIC) is an accounting term found on Vertex Pharmaceuticals Balance Sheet under Shareholders Equity. It is the value of the shares of the company above what they were issued it. The basic calculation is as follow: (Issue Price - Par Value) x Vertex Pharmaceuticals Shares Outstanding. Additional Paid In Capital is not affected by secondary trading of Vertex Pharmaceuticals shares and does not have any impact on the value of APIC. It is the excess amount paid by investors over the par value of a company's shares, representing the additional capital contributed by shareholders. Vertex Pharmaceuticals' Additional Paid In Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Additional Paid In Capital10 Years Trend
Slightly volatile
   Additional Paid In Capital   
       Timeline  

Vertex Additional Paid In Capital Regression Statistics

Arithmetic Mean4,592,613,120
Geometric Mean0.00
Coefficient Of Variation80.67
Mean Deviation3,444,459,840
Median7,157,362,000
Standard Deviation3,704,965,475
Sample Variance13726769.2T
Range8.6B
R-Value0.88
Mean Square Error3222192.8T
R-Squared0.78
Slope687,687,597
Total Sum of Squares205901537.6T

Vertex Additional Paid In Capital History

20258.6 B
20248.2 B
20177.2 B
20166.5 B

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Additional Paid In Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Additional Paid In Capital8.2 B8.6 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.